Effectiveness of entecavir treatment and predictive factors for virologic response

Revista Espanola de Enfermedades Digestivas

Volumn 106, Issue 5, 2014, Pages 305-311

  Preda, Carmen Monica ^a   Baicus, Cristian ^b   Negreanu, Lucian ^c   Tugui, Letitia ^a   Olariu, Sandra Viviana ^a   Andrei, Adriana ^a   Zambatu, Ileana ^c   Diculescu, Mircea Mihai ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b Internal Medicine Department N Ghe Lupu Hospital   (Romania)

^c Universitary Emergency Hospital   (Romania)

Author keywords

Chronic hepatitis B; Entecavir; Hbe antigen negative; HBe antigen positive

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS B; COMORBIDITY ASSESSMENT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEROCONVERSION; TREATMENT OUTCOME; VIRUS LOAD; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; DRUG EFFECTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; PROGNOSIS; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84930704134     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;34 (Supl.1):S1-3.
2. Romano L, Paladini S, Van Damme P, Zanetti AR The worldwide impact of vaccination on the control and protection of viral hepatitis B. Digestive and Liver Disease January 2011;43 (Supl. 1):S2-S7.
3. Iavarone M, Colombo M HBV-related HCC, clinical issues and therapy. Digestive and Liver Disease. 2011;43 (Supl.1):32-39.
4. Olivari N, Pasino M, Zanni S, D’Onofrio M, Martone E, Donato F, et al. Natural course of hepatitis B e antigen positive chronic hepatitis B: Mortality after 25 years. Digestive and Liver Disease 2007;39:25.
5. Manzat Saplacan RM, Mircea PA, Valean SD, Miu N, Burac L, Valean C, et al. The long-term evolution of chronic hepatitis B acquired in childhood. J Gastrointestin Liver Dis 2009;18: 433-8.
6. Leung N. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide Analogues. Liver Int 2011:85-9.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012. Available at: http://dx.doi.org/10.1016/j. jhep.2012.02.010
8. Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, et al. Efficacy and safety of peginterferon alpha-2a (40 kD) in Hbe Ag-positive chronic hepatitis B patients. J Gastrointestin Liver Dis 2009;18:425-31.
9. Innaimo SF, Seifer M, Bisacchi G, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-8.
10. Ide T, Sata M, Chayama K, Shindo M, Toyota J, Mochida S, et al. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol Int 2010;4:594-600.
11. Chang TT, Gish RG, Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for Hbe Ag-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
12. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl. J Med 2006;354:1011-20.
13. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HbeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49.
14. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44.
15. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, et al. Tenofovir and entecavir are most effective antiviral agents for CHB – a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218-29.
16. Shouval D, Lai C-L, Chang T-T, Gadano A, Wu S-S, Halota W, et al. Three years of entecavir (ETV) re-treatment of HbeAg-negative ETV patients who previously discontinued ETV treatment: Results from study ETV-901. Hepatology 2008;48:722A.
17. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.
18. Gheorghe L, Csiki IE, Iacob S, Gheorghe C. The prevalence and risk factors of hepatitis B virus infection in Romania: A nationwide survey. Eur J Gastroenterol Hepatol 2013;25:56-94.
19. Constantinescu I, Nedelcu F, Toader MA, Vasile D. Clinical and therapeutical importance of HBV genotyping in Romania. Romanian Journal of Hepatology 2006;2:43-8.
20. Chien RN. On-treatment monitoring of chronic hepatitis B virus infection: An Asian–Pacific perspective. J Gastroenterol Hepatol 2010;25:852-7.
21. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-209.
22. Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: A randomized double-blind trial in China. Hepatol Int 2007;1:365-72.
23. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: Viral suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011;106:1264-71.
24. Colonno RJ, Rose RE, Pokornowsky K, Baldick CJ, Eggers B, Xu D, et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007; 46(Supl. 1):S294.
25. Marcellin P, Liang J. A personalized approach to optimize hepatitis B treatment in treatment-naive patients. Antiviral Therapy 2010;15 (Supl. 3):53-9.
26. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94.
27. Tenney D, Pokorowsky KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008;2: S77.
28. Papatheodoridis GV. Treatment of HbeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. Liver Int 2011;31(Supl.1):95-103.
29. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: From clinical trials to clinical practice. J Viral Hepat 2012;19:377-86.
30. Buti M, Morillas RM, Prieto M, Diago M, Pérez J, Solà R, et al. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. Eur J Gastroenterol Hepatol 2012;24:535-42.